Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 21Brain Neoplasms 7Neoplasms 5Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Lung Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Hematologic Neoplasms 3Thyroid Neoplasms 2Lymphoma 2Leukemia, Hairy Cell 2Glioma 2Endometrial Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Skin Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Peripheral Nervous System Neoplasms 1

Interventions

Radiotherapy 2Proton Therapy 2Mental Status and Dementia Tests 2trametinib 1tozuleristide 1tovorafenib 1tocilizumab 1dabrafenib 1cobimetinib 1binimetinib 1antineoplaston AS 2-1 1antineoplaston A10 1Vemurafenib 1Transurethral Resection of Bladder 1Surgical Procedures, Operative 1Qsymia 1Phentermine 1Oxytocin 1Methionine 1Memantine 1Medication Errors 1Ginkgo biloba extract 1Exenatide 1Donepezil 1Contrast Media 1CKD732 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Craniopharyngioma × binimetinib × Clear all
NCT05286788 2026-04-08

MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma

Nationwide Children's Hospital

Phase 2 Recruiting
38 enrolled
CNS

Craniopharyngioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡